Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
HER3 could be a key target in cancer-drug design
July 21st, 2005
HER3 could be a key target in cancer-drug design. "Two members of the EGF receptor family, HER2 and HER3, act as key oncogenes in breast cancer cells. A MAb against HER2, trastuzumab, interferes with HER2 signaling and is therapeutically effective in humans," scientists in Germany reported. "Here, we explored the biologic effects of an antibody against HER3 (alpha-HER3(ECD)) in the invasive breast cancer cell lines MCF-7 ADR and MDA-MB-468. Pretreating the breast cancer cells with alpha-HER3(ECD) prior to Heregulin stimulation caused significant reduction or the migratory and proliferative properties. This reduction is due to a substantial decrease...
Source: Women's Health Weekly (2005-07-21)
|
